Cargando…

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group

Almost one-third of all patients with chronic lymphocytic leukemia (CLL) express stereotyped B-cell receptor immunoglobulins (BcR IG) and can be assigned to distinct subsets, each with a particular BcR IG. The largest stereotyped subsets are #1, #2, #4 and #8, associated with specific clinico-biolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jaramillo, Sonia, Agathangelidis, Andreas, Schneider, Christof, Bahlo, Jasmin, Robrecht, Sandra, Tausch, Eugen, Bloehdorn, Johannes, Hoechstetter, Manuela, Fischer, Kirsten, Eichhorst, Barbara, Goede, Valentin, Hallek, Michael, Döhner, Hartmut, Rosenquist, Richard, Ghia, Paolo, Stamatopoulos, Kostas, Stilgenbauer, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604575/ https://www.ncbi.nlm.nih.gov/pubmed/33131249 http://dx.doi.org/10.3324/haematol.2019.231027

Ejemplares similares

P605: IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
por: Iatrou, Anastasia, et al.
Publicado: (2023)

Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients
por: Bloehdorn, Johannes, et al.
Publicado: (2021)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

Distinctive Signaling Profiles With Distinct Biological and Clinical Implications in Aggressive CLL Subsets With Stereotyped B-Cell Receptor Immunoglobulin
por: Gerousi, Marina, et al.
Publicado: (2021)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach
por: Colombo, Monica, et al.
Publicado: (2020)

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
por: Herling, Carmen D., et al.
Publicado: (2020)

Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL
por: Agathangelidis, Andreas, et al.
Publicado: (2022)

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
por: Al-Sawaf, Othman, et al.
Publicado: (2021)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

Assessing Patients’ Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece
por: Karamanidou, Christina, et al.
Publicado: (2021)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

CLL stereotyped B-cell receptor immunoglobulin sequences are recurrent in the B-cell repertoire of healthy individuals: Apparent lack of central and early peripheral tolerance censoring
por: Vergani, Stefano, et al.
Publicado: (2023)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
por: Zapatka, Marc, et al.
Publicado: (2021)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
por: Fürstenau, Moritz, et al.
Publicado: (2019)

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
por: Kutsch, Nadine, et al.
Publicado: (2020)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Pflug, Natali, et al.
Publicado: (2021)

Infrequent “chronic lymphocytic leukemia-specific” immunoglobulin stereotypes in aged individuals with or without low-count monoclonal B-cell lymphocytosis
por: Agathangelidis, Andreas, et al.
Publicado: (2021)

Challenges and Solutions for Collecting and Analyzing Real World Data: The Eric CLL Database as an Illustrative Example
por: Chatzidimitriou, Anastasia, et al.
Publicado: (2020)

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
por: Fink, A M, et al.
Publicado: (2013)

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis
por: Schilhabel, Anke, et al.
Publicado: (2022)

Targeted therapy in CLL: changing the treatment paradigm
por: Schneider, Christof, et al.
Publicado: (2019)

Lamin B1 regulates somatic mutations and progression of B-cell malignancies
por: Klymenko, T, et al.
Publicado: (2018)

Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations
por: Agathangelidis, Andreas, et al.
Publicado: (2018)

Editorial: Biology and treatment of high-risk CLL
por: Tausch, Eugen, et al.
Publicado: (2023)

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription
por: Edelmann, Jennifer, et al.
Publicado: (2020)

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group
por: von Tresckow, Julia, et al.
Publicado: (2023)

Vaccination against COVID-19: a challenge in CLL
por: Eichhorst, Barbara
Publicado: (2021)

DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy
por: Yosifov, Deyan Yordanov, et al.
Publicado: (2020)

Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity
por: Sofou, Electra, et al.
Publicado: (2022)

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
por: Freeman, C L, et al.
Publicado: (2016)

Genetic Lesions in Russian CLL Patients with the Most Common Stereotyped Antigen Receptors
por: Biderman, Bella V., et al.
Publicado: (2023)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
por: Stilgenbauer, Stephan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4c6asn102eh1qnovoucl9a19mm